Novo Nordisk A/S (Novo Nordisk A/S) Change In Payables And Accrued Expense : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Change In Payables And Accrued Expense?

Novo Nordisk A/S's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $0 Mil. It means Novo Nordisk A/S's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Novo Nordisk A/S's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $1,110 Mil. It means Novo Nordisk A/S's Accounts Payable & Accrued Expense increased by $1,110 Mil from Dec. 2022 to Dec. 2023 .

Novo Nordisk A/S Change In Payables And Accrued Expense Historical Data

The historical data trend for Novo Nordisk A/S's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Change In Payables And Accrued Expense Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-15.32

38.92

476.83

733.32

1,110.05

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Novo Nordisk A/S Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Novo Nordisk A/S Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.